Molecular Pharmaceutics
[ASAP] Human Immortalized Cell-Based Blood–Brain Barrier Spheroid Models Offer an Evaluation Tool for the Brain Penetration Properties of Macromolecules
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00120
Molecular Pharmaceutics
[ASAP] Fitting Pharmacodynamic Data to the <italic toggle=”yes”>E</italic><sub><italic toggle=”yes”>max</italic></sub> Model to Assess the Inherent Potency of Topical Corticosteroids
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00254
Molecular Pharmaceutics
[ASAP] Water-Resistant Drug–Polymer Interaction Contributes to the Formation of Nano-Species during the Dissolution of Felodipine Amorphous Solid Dispersions
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00250
Molecular Pharmaceutics
[ASAP] Antiallergic Treatment of Bariatric Patients: Potentially Hampered Solubility/Dissolution and Bioavailability of Loratadine, but Not Desloratadine, Post-Bariatric Surgery
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00292
Molecular Pharmaceutics
[ASAP] Coupling Chlorin-Based Photosensitizers and Histone Deacetylase Inhibitors for Photodynamic Chemotherapy
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00170
Molecular Pharmaceutics
[ASAP] Structure–Activity Relationships and Pharmacokinetics of <sup>111</sup>In-Labeled Glucagon-like Peptide‑1 Receptor-Targeting Exendin‑4 Derivatives Conjugated with Albumin Binder Moieties
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00201
Molecular Pharmaceutics
[ASAP] Comparison of the Effectiveness of IgG Antibody versus F(ab′)<sub>2</sub> Antibody Fragment in CTLA4-Targeted Near-Infrared Photoimmunotherapy
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00242
Molecular Pharmaceutics
[ASAP] Synthesis and Evaluation of Novel <sup>111</sup>In-Labeled Picolinic Acid-Based Radioligands Containing an Albumin Binder for Development of a Radiotheranostic Platform
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00071
Molecular Pharmaceutics
[ASAP] Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D<sub>2</sub> and Histamine H<sub>3</sub> Receptors: A PET Study in Healthy Rats
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00121
Molecular Pharmaceutics
[ASAP] Recent Advances in Peptides-Based Stimuli-Responsive Materials for Biomedical and Therapeutic Applications: A Review
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.1c00983